Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?

被引：0
作者：
Laila M. Sherief
Osama A. Gaber
Hala Mosaad Youssef
Hanan S. Sherbiny
Wesam a Mokhtar
Asmaa A. A. Ali
Naglaa M. Kamal
Yehia H. Abdel Maksoud
机构：
[1] Zagazig University,Pediatric Department, Faculty of Medicine
[2] Zagazig University,Biochemistry Department, Faculty of Medicine
[3] University of Bisha (UB),Pediatric Department, Collage of Medicine
[4] Cairo University,Pediatric Department, Faculty of Medicine
[5] Benha University,Pediatric Department, Faculty of Medicine
来源：
Italian Journal of Pediatrics | / 46卷
关键词：
Factor VIII inhibitor; Hemophilia; Intron 22 inversion mutation; Children;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 28 条
  • [1] Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?
    Sherief, Laila M.
    Gaber, Osama A.
    Youssef, Hala Mosaad
    Sherbiny, Hanan S.
    Mokhtar, Wesam a
    Ali, Asmaa A. A.
    Kamal, Naglaa M.
    Abdel Maksoud, Yehia H.
    ITALIAN JOURNAL OF PEDIATRICS, 2020, 46 (01)
  • [2] Factor VIII-intron 1 inversion of Hemophilia A patients in West Anatolia
    Pehlivan, M.
    Pehlivan, S.
    Buyukkececi, F.
    Cagirgan, S.
    Yilmaz, M.
    Omay, Bedii S.
    Tombuloglu, M.
    Kavakli, K.
    BALKAN JOURNAL OF MEDICAL GENETICS, 2007, 10 (01) : 49 - 50
  • [3] Prominent Mutation of Intron 22 Inversion in Sporadic Hemophilia: Is It Worth the Antenatal Screening?
    Sasanakul, Werasak
    Chuansumrit, Ampaiwan
    Sirachainan, Nongnuch
    Kadegasem, Praguywan
    APPLICATION OF CLINICAL GENETICS, 2022, 15 : 49 - 54
  • [4] Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A
    Mancuso, M. E.
    Mannucci, P. M.
    Rocino, A.
    Garagiola, I.
    Tagliaferri, A.
    Santagostino, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (05) : 781 - 790
  • [5] Factor VIII Products and Inhibitor Development in Severe Hemophilia A
    Gouw, Samantha C.
    van der Bom, Johanna G.
    Ljung, Rolf
    Escuriola, Carmen
    Cid, Ana R.
    Claeyssens-Donadel, Segolene
    van Geet, Christel
    Kenet, Gili
    Makipernaa, Anne
    Molinari, Angelo Claudio
    Muntean, Wolfgang
    Kobelt, Rainer
    Rivard, George
    Santagostino, Elena
    Thomas, Angela
    van den Berg, H. Marijke
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (03) : 231 - 239
  • [6] FACTOR-VIII INHIBITORS IN PATIENTS WITH HEMOPHILIA-A - EPIDEMIOLOGY OF INHIBITOR DEVELOPMENT AND INDUCTION OF IMMUNE TOLERANCE FOR FACTOR-VIII
    KREUZ, W
    BECKER, S
    LENZ, E
    MARTINEZSAGUER, I
    ESCURIOLAETTINGSHAUSEN, C
    FUNK, M
    EHRENFORTH, S
    AUERSWALD, G
    KORNHUBER, B
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1995, 21 (04) : 382 - 389
  • [7] Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: Similarities with the intron 22 inversion mutation in human hemophilia
    Hough, C
    Kamisue, S
    Cameron, C
    Notley, C
    Tinlin, S
    Giles, A
    Lillicrap, D
    THROMBOSIS AND HAEMOSTASIS, 2002, 87 (04) : 659 - 665
  • [8] Factor VIII gene variants and inhibitor risk in African American hemophilia A patients
    Gunasekera, Devi
    Ettinger, Ruth A.
    Fletcher, Shelley Nakaya
    James, Eddie A.
    Liu, Maochang
    Barrett, John C.
    Withycombe, Janice
    Matthews, Dana C.
    Epstein, Melinda S.
    Hughes, Richard J.
    Pratt, Kathleen P.
    BLOOD, 2015, 126 (07) : 895 - 904
  • [9] The prevalence of factor VIII inhibitor in patients with severe hemophilia-A and its clinical characteristics
    Harijadi
    Gatot, Djajadiman
    Akib, Arwin A. P.
    PAEDIATRICA INDONESIANA, 2005, 45 (7-8) : 177 - 181
  • [10] Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A
    Hart, Daniel P.
    Uzun, Nazmiye
    Skelton, Stuart
    Kakoschke, Alison
    Househam, Jacob
    Moss, David S.
    Shepherd, Adrian J.
    HAEMATOLOGICA, 2019, 104 (03) : 599 - 608
123